Regulation of metabolism is emerging as a central mechanism to control cellular identity and function. Extensive research in the last few years has revealed that the PI3K pathway is at the forefront of establishing metabolic changes required for immune cell growth, proliferation, migration, and differentiation. However, we currently have a limited understanding of how signaling through the PI3K pathway is tightly regulated during immune responses and immune cell development. Although a growing number of miRNAs have been shown to target important metabolic pathways, including the PI3K pathway itself, almost nothing is known regarding metabolic regulation by miRNAs in the context of the immune system. Recently, we revealed that the miR-181 family is a metabolic rheostat in vivo through the nonredundant regulation of PTEN. Over the next few years, additional miRNAs with the capacity to regulate various aspects of metabolism in immune cells are likely to be identified. We propose that these miRNAs will form a network to finely tune cellular metabolic status and that miR-181 will function as the primary metabolic rheostat of this network.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1101/sqb.2013.78.020024 | DOI Listing |
Background And Aim: The high rate of tumor growth results in an increased need for amino acids. As solute carriers (SLC) transporters are capable of transporting different amino acids, cancer may develop as a result of these transporters' over-expression due to their complex formation with other biological molecules. Therefore, this review investigated the role of SLC transporters in the progression of cancer.
View Article and Find Full Text PDFDrug Des Devel Ther
January 2025
Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Introduction: The mechanism of remimazolam, a benzodiazepine that activates γ-aminobutyric acid a (GABAa) receptors, in cerebral ischemia/reperfusion (I/R) injury is not well understood. Therefore, we explored whether remimazolam activates protein kinase B (AKT)/glycogen synthase kinase-3β (GSK-3β)/nuclear factor erythroid 2-related factor 2 (NRF2) to attenuate brain I/R injury in transcerebral I/R-injured rats and transoxygenic glucose deprivation/reperfusion (OGD/R)-injured SY5Y cells.
Material And Methods: Remimazolam was added at the beginning of cell and rat reperfusion, and the PI3K/AKT inhibitor LY294002 was added to inhibit the AKT/GSK-3β/NRF2 pathway 24 h before cellular OGD/R treatment and 30 min before rat brain I/R treatment.
Oncol Lett
March 2025
Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Adiponectin (ADN) regulates DNA synthesis, cell apoptosis and cell cycle to participate in the pathology and progression of glioblastoma. The present study aimed to further explore the effect of ADN on temozolomide (TMZ) resistance in glioblastoma and the underlying mechanism of action. Glioblastoma cell lines (U251 and U87-MG cells) were treated with ADN and TMZ at different concentrations; subsequently, 3.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Department of Orthopaedics, Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong Province, People's Republic of China.
Background: Panax notoginseng (Burk.) F. H.
View Article and Find Full Text PDFJ Liver Cancer
January 2025
Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background/aims: Hepatocellular carcinoma (HCC) is a malignant cancer with an increasing incidence worldwide. Although numerous efforts have been made to identify effective therapies for HCC, current strategies have limitations. We present a new approach for targeting L-arginine and argininosuccinate synthetase 1 (ASS1).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!